The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

NCT07381634 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
IrAE

Interventions

DRUG: ondansetron

Sponsor

First Affiliated Hospital of Wenzhou Medical University